摘要
目的:评价疏风解毒胶囊对急性上呼吸道感染患者伴发热的临床疗效。方法:选取2014年4月—2017年4月间收治的急性上呼吸道感染伴发热患者87例资料,按数表法将其分成对照组43例和观察组44例;对照组患者给予氨伽黄敏片和板蓝根颗粒治疗,观察组患者给予疏风解毒胶囊治疗,比较两组患者治疗后的总有效率和临床症状复常时间的差异。结果:观察组患者治疗后的总有效率为93.2%和再发热率为4.54%优于对照组为74.42%和再发热率为27.91%(P<0.05);治疗后观察组患者发热和咳嗽复常时间早于对照组(P<0.05),CRP和ESR水平测得值均低于对照组(P<0.05)。结论:采用疏风解毒胶囊治疗急性上呼吸道感染伴发热患者的疗效较为确切,有效改善了症状,降低了再发热率。
Objective： to evaluate the clinical efficacy of Shufengjiandu capsules in fever patients accompanied with acute upper respiratory tract infection. Methods： from April 2014 to April 2017, 87 cases of patients with acute upper respiratory tract infection associated with fever were selected. They were divided into control group（43 cases） and observation group（44 cases）. Patients in the control group were treated with amagraxine tablets and Banlangen granules, while patients in the observation group were treated with Shufengjiandu capsules. The differences of total effective rate and time of recurrence of clinical symptoms were compared between the two groups. Results： The total effective rate of patients in the observation group after treatment was 93.2% and the refever rate was 4.54%, which was better than that in the control group（74.42%） and 27.91%（P〈0.05）. After treatment, fever and cough returned earlier in the observation group than the control group（P〈0.05）, and CRP and ESR levels were lower than those in the control group（P〈0.05）. Conclusion： The curative effect of the treatment of acute upper respiratory tract infection patients accompanied with fever with Shufengjiandu capsule is relatively accurate, which can effectively improve the symptoms and reduce the refever rate.
作者
王雷
邱晓梅
WANG Lei;QIU Xiao-mei(Nanyang No.1 People＇s Hospital,Nanyang He＇nan 473000)
出处
《抗感染药学》
2018年第8期1406-1408,共3页
Anti-infection Pharmacy
关键词
急性上呼吸道感染
发热
疏风解毒胶囊
临床疗效
acute upper respiratory tract infection
fever
Shufengjiandu capsule
clinical efficacy
